Analysts forecast that Adamis Pharmaceuticals Corp (NASDAQ:ADMP) will announce earnings per share of ($0.16) for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Adamis Pharmaceuticals’ earnings. The highest EPS estimate is ($0.09) and the lowest is ($0.19). Adamis Pharmaceuticals posted earnings of ($0.21) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 23.8%. The firm is expected to report its next quarterly earnings report on Monday, August 13th.
On average, analysts expect that Adamis Pharmaceuticals will report full year earnings of ($0.69) per share for the current fiscal year, with EPS estimates ranging from ($0.81) to ($0.54). For the next fiscal year, analysts anticipate that the company will post earnings of ($0.34) per share, with EPS estimates ranging from ($0.61) to $0.12. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Adamis Pharmaceuticals.
Adamis Pharmaceuticals (NASDAQ:ADMP) last released its quarterly earnings results on Friday, August 10th. The specialty pharmaceutical company reported ($0.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.10). Adamis Pharmaceuticals had a negative return on equity of 71.68% and a negative net margin of 207.24%. The company had revenue of $3.92 million for the quarter, compared to analysts’ expectations of $4.14 million.
ADMP has been the subject of several analyst reports. B. Riley upped their price target on Adamis Pharmaceuticals to $7.50 and gave the stock a “buy” rating in a research note on Tuesday, July 3rd. Maxim Group upped their price objective on Adamis Pharmaceuticals to $13.00 and gave the stock a “buy” rating in a report on Monday, July 2nd. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Adamis Pharmaceuticals in a report on Monday, July 2nd. Zacks Investment Research raised Adamis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 price objective on the stock in a report on Tuesday, July 24th. Finally, ValuEngine raised Adamis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $8.40.
Shares of Adamis Pharmaceuticals remained flat at $$3.25 during trading hours on Friday, Marketbeat.com reports. The stock had a trading volume of 537,007 shares, compared to its average volume of 656,420. Adamis Pharmaceuticals has a twelve month low of $2.35 and a twelve month high of $5.85. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.88 and a quick ratio of 1.57. The stock has a market capitalization of $108.52 million, a PE ratio of -3.61 and a beta of 0.45.
A number of hedge funds have recently made changes to their positions in ADMP. Wells Fargo & Company MN grew its holdings in Adamis Pharmaceuticals by 1,050.3% in the fourth quarter. Wells Fargo & Company MN now owns 28,182 shares of the specialty pharmaceutical company’s stock valued at $124,000 after purchasing an additional 25,732 shares during the last quarter. Dimensional Fund Advisors LP acquired a new stake in Adamis Pharmaceuticals in the first quarter valued at $244,000. Northern Trust Corp grew its holdings in Adamis Pharmaceuticals by 50.7% in the first quarter. Northern Trust Corp now owns 139,536 shares of the specialty pharmaceutical company’s stock valued at $489,000 after purchasing an additional 46,924 shares during the last quarter. Finally, BlackRock Inc. grew its holdings in Adamis Pharmaceuticals by 7.7% in the second quarter. BlackRock Inc. now owns 293,328 shares of the specialty pharmaceutical company’s stock valued at $939,000 after purchasing an additional 20,871 shares during the last quarter. 10.72% of the stock is currently owned by hedge funds and other institutional investors.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
Recommended Story: Google Finance Portfolio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.